[go: up one dir, main page]

FR3108031B1 - Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes - Google Patents

Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes Download PDF

Info

Publication number
FR3108031B1
FR3108031B1 FR2002475A FR2002475A FR3108031B1 FR 3108031 B1 FR3108031 B1 FR 3108031B1 FR 2002475 A FR2002475 A FR 2002475A FR 2002475 A FR2002475 A FR 2002475A FR 3108031 B1 FR3108031 B1 FR 3108031B1
Authority
FR
France
Prior art keywords
back pain
prevention
treatment
nmn
corresponding compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
FR2002475A
Other languages
English (en)
Other versions
FR3108031A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71661990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3108031(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to FR2002475A priority Critical patent/FR3108031B1/fr
Priority to PCT/EP2021/056318 priority patent/WO2021180915A1/fr
Priority to CA3175088A priority patent/CA3175088A1/fr
Priority to US17/910,581 priority patent/US20230172959A1/en
Priority to CN202180032248.4A priority patent/CN115484962A/zh
Priority to EP21710972.7A priority patent/EP4117676A1/fr
Priority to AU2021236358A priority patent/AU2021236358A1/en
Priority to JP2022555073A priority patent/JP2023518206A/ja
Publication of FR3108031A1 publication Critical patent/FR3108031A1/fr
Publication of FR3108031B1 publication Critical patent/FR3108031B1/fr
Application granted granted Critical
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables, pour son utilisation dans la prévention et/ou le traitement d’une douleur dorsale telle qu’une lombalgie, une dorsalgie ou une cervicalgie, de préférence une lombalgie chronique, ainsi que les compositions le comprenant.
FR2002475A 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes Revoked FR3108031B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2002475A FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
CN202180032248.4A CN115484962A (zh) 2020-03-12 2021-03-12 烟酰胺单核苷酸或其某些衍生物用于预防和/或治疗腰背颈部疼痛的用途，以及相应的组合物
CA3175088A CA3175088A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucleotide ou de certains de ses derives pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
US17/910,581 US20230172959A1 (en) 2020-03-12 2021-03-12 Use of nmn for the prevention and/or treatment of a back pain and corresponding compositions
PCT/EP2021/056318 WO2021180915A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
EP21710972.7A EP4117676A1 (fr) 2020-03-12 2021-03-12 Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
AU2021236358A AU2021236358A1 (en) 2020-03-12 2021-03-12 Use of a nicotinamide mononucleotide or some of its derivatives for preventing and/or treating dorsal pain, and corresponding compositions
JP2022555073A JP2023518206A (ja) 2020-03-12 2021-03-12 背部痛を予防および／または治療するためのニコチンアミドモノヌクレオチドまたはその誘導体のいくつかの使用、ならびに対応する組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002475A FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
FR2002475 2020-03-12

Publications (2)

Publication Number Publication Date
FR3108031A1 FR3108031A1 (fr) 2021-09-17
FR3108031B1 true FR3108031B1 (fr) 2024-02-16

Family

ID=71661990

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2002475A Revoked FR3108031B1 (fr) 2020-03-12 2020-03-12 Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes

Country Status (8)

Country Link
US (1) US20230172959A1 (fr)
EP (1) EP4117676A1 (fr)
JP (1) JP2023518206A (fr)
CN (1) CN115484962A (fr)
AU (1) AU2021236358A1 (fr)
CA (1) CA3175088A1 (fr)
FR (1) FR3108031B1 (fr)
WO (1) WO2021180915A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1099319S1 (en) 2024-06-07 2025-10-21 Stryker European Operations Limited Bone plate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US8690857B2 (en) * 2010-07-23 2014-04-08 Aleeva Medical Inc. Alleviate back pain with lactic acid inhibitors
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
MX2016016071A (es) * 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
JP7193232B2 (ja) * 2015-04-28 2022-12-20 ニューサウス イノベーションズ ピーティーワイ リミテッド 化学療法及び放射線療法誘発性認知機能障害、神経障害及び不活動を治療するためのｎａｄ＋の標的化
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
US10722529B2 (en) * 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease
CN106659729A (zh) * 2015-12-11 2017-05-10 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物
CN107233352A (zh) * 2017-06-20 2017-10-10 同济大学 烟酰胺腺嘌呤二核苷酸在制备治疗炎性痛药物中的应用
WO2019209840A1 (fr) * 2018-04-23 2019-10-31 Elysium Health, Inc. Procédés et compositions pour le traitement de la polyarthrite rhumatoïde
CN108888769A (zh) * 2018-07-30 2018-11-27 郑州兰茜生物工程有限公司 一种颈肩腰腿痛用并具强筋健络功能的生物制剂
CA3153239A1 (fr) * 2019-09-09 2021-03-18 Nuvamid Sa Utilisation de nmn pour la prevention et/ou le traitement de la douleurnet compositions correspondantes
JP7707171B2 (ja) * 2019-12-20 2025-07-14 ヌバミッド エスエー 新規のニコチンアミドジヌクレオチド誘導体およびその使用
FR3106056B1 (fr) * 2020-01-13 2021-12-17 Nuvamid Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes

Also Published As

Publication number Publication date
AU2021236358A1 (en) 2022-10-06
CA3175088A1 (fr) 2021-09-16
FR3108031A1 (fr) 2021-09-17
EP4117676A1 (fr) 2023-01-18
WO2021180915A1 (fr) 2021-09-16
CN115484962A (zh) 2022-12-16
JP2023518206A (ja) 2023-04-28
US20230172959A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
BR112023012301A2 (pt) Combinações farmacêuticas que compreendem um inibidor de kras g12c e usos de um inibidor de kras g12c para o tratamento de cânceres
FR3106056B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MX386873B (es) Composiciones farmacéuticas y usos de las mismas para tratar enfermedades cardiovasculares
MA34474B1 (fr) Agonistes de gpr40
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
BR112022015151A2 (pt) Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
FR3108031B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
CA3250054A1 (fr) Didéhydro-3'-désoxy-4'-éthynylthymidines, composés apparentés et leur utilisation dans le traitement d'affections médicales
FR3108032B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
JOP20220038A1 (ar) عوامل مضادة للملاريا
FR3110836B1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
MX2025011086A (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
MX2023007420A (es) Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
FR3100449B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
Pérez-Lamas et al. Efficacy of consolidation therapy with ponatinib 15mg on treatment-free remission rate in patients with chronic myeloid leukemia. Results of the Ponazero trial
EA202192257A1 (ru) Комбинация кремния и магния для предупреждения и лечения мышечных судорог

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210917

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

OR Opposition filed

Effective date: 20241118

RT Complete renunciation

Effective date: 20250217

SI End of court proceedings without consequences for the ip right

Effective date: 20250407